Glucagon-like peptide modulators or sodium‒glucose cotransporter 2 inhibitors constitute the second line of therapy for stimulating insulin release and facilitating glucose uptake into cells [93], with both classes now recognized for their cardiovascular benefits beyond glucose lowering, including reduction in heart failure risk and adverse cardiac remodeling. This evidence concerns the gene GCG and heart failure.